Management of over-anticoagulation in warfarinised hospital patients

Journal of Pharmacy Practice and Research

Volumn 39, Issue 1, 2009, Pages 13-18

  Bajorek, Beata V ^a   Yau, Leanne ^b   Lee, Kevin ^b   Zulueta, Wayne ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; AMITRIPTYLINE; ANTIBIOTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PANTOPRAZOLE; PHENYTOIN; PROTHROMBIN; PROTHROMBINEX; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIMVASTATIN; THYROXINE; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATTRIBUTABLE RISK; BLEEDING TENDENCY; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEART ATRIUM FIBRILLATION; HEMOPTYSIS; HOSPITAL PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LACERATION; LEG INJURY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MELENA; OUTCOME ASSESSMENT; OVERANTICOAGULATION; PREVALENCE; PROSTHETIC VALVE THROMBOSIS; RISK FACTOR; SIDE EFFECT; SKIN BRUISING;

EID: 65549153682     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2009.tb00697.x     Document Type: Article

References (16)

1. Baker R, Coughlin P, Gallus A, Harper P, Salem H, Wood E. Warfarin reversal: consensus guidelines on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-7.
2. Hanley J. Warfarin reversal. J Clin Pathol 2004; 57: 1132-9.
3. Glasheen J. Preventing warfarin-related bleeding. South Med J 2005; 98: 96-103.
4. Isbister G, Dawson A, Isbister J. Recommendations for the management of over-anticoagulation with warfarin. Emerg Med 2001; 13: 469-72.
5. Baker P, Gleghorn A, Tripp T, Paddon K, Eagleton H, Keeling D. Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol 2006; 133: 331-6.
6. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127: 1515-22.
7. Horton J, Bushwick B. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician 1999; 60: 764, 766.
8. Gumulec J, Kessler P, Penka M, Klodova D, Kralova S, Brejcha M, et al. Hemorrhagic complications during warfarin treatment. Vnitr Lek 2006; 1: 79-91.
9. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin Geriatr Med 2006; 22: 17-32.
10. Prybys K. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am 2004; 22: 845-63.
11. Hylek E. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vase Med 2003; 3: 271-8.
12. Makris M. Management of excessive anticoagulation or bleeding. Semin Vase Med 2003; 3: 279-84.
13. Beyth R. Management of haemorrhagic complications associated with oral anticoagulant treatment. Expert Opin Drug Saf 2002; 1: 129-36.
14. Chai S, Macik B. Improving the safety profile of warfarin. Semin Hematol 2002; 39: 179-86.
15. NSW Department of Health (Quality and Safety Branch). Warfarin: guidelines for prescribing, dispensing and administering warfarin. Safety Notice 12 April 2007. Available from .
16. Australian Council for Safety and Quality in Health Care. National inpatient medication chart pilot aggregate data report. Canberra: Australian Council for Safety and Quality in Health Care; 2005. Available from .